The FDA yesterday said that interim data from a post-approval study of Abiomed‘s (NSDQ:ABMD) Impella RP heart pump system showed only a 17.4% survival rate, approximately 55% lower than the rate noted in the premarket study of the device. The federal watchdog said that it is currently evaluating data from the study and that it will […]
Abiomed touts CE Mark for Impella Connect, posts Street-beating FY2019 Q3 earnings
Abiomed (NSDQ:ABMD) said today that it won CE Mark approval in the European Union for its Impella Connect cloud-based Impella heart pump console and released fiscal year 2019 third quarter earnings that topped expectations on Wall Street. The Danvers, Mass.-based company said its Impella Connect is a cloud-based platform that allows physicians and hospital staff to […]
Abiomed wants whistleblower to cough up employment records
Abiomed (NSDQ:ABMD) yesterday asked a federal judge to force whistleblower Max Bennett to cough up his employment records with another company, countering his retaliatory termination claim by alleging that it fired him for lying about the circumstances of his departure from his last job. Documents unsealed in March 2018 revealed that Max Bennett accused the Danvers, Mass.-based […]
10 of the best performing medical device stocks of 2018
Updated Jan. 8, 2019 Medical device company stocks are not looking as rosy as they did two months ago, but the medtech industry still appears to be resisting the overall downward trend in stock markets, according to a Medical Design & Outsourcinganalysis. More than half of the roughly 100 largest medical device companies in the world […]
Ex-Abiomed exec loses $2m lawsuit
A former Abiomed (NSDQ:ABMD) Asia VP lost a lawsuit that sought $2.1 million in damages, alleging unfair termination and the denial of an options deal tied to Japanese approval of its Impella heart pump. The Danvers, Mass.-based heart pump maker hired the plaintiff, Keisuke Suzuki, in 2010 to help it pursue Japanese regulatory approval for the Impella […]
Abiomed jumps on fiscal Q3 prelims, raised outlook | Wall Street Beat
Abiomed (NSDQ:ABMD) shares got a jump today from its preliminary fiscal third-quarter numbers and an improved outlook for the rest of its fiscal year. The Danvers, Mass.-based heart pump maker said it expects to post fiscal Q3 sales of roughly $200.6 million, representing a 30.3% increase over its fiscal Q3 top line. Abiomed also raised […]
Abiomed puts $15m into Shockwave
Abiomed (NSDQ:ABMD) plans to invest $15 million in Shockwave Medical and collaborate on a training and education program in the U.S. and Germany, according to a newly-inked deal between the two companies. Shockwave’s intravascular lithotripsy technology uses sonic pressure waves to crack vascular calcium in the vessel wall, allowing arteries to expand under low pressure. The […]
Abiomed shares slide despite Impella CP trial success
Abiomed (NSDQ:ABMD) shares fell approximately 13.1% yesterday despite the company announcing positive results from a pilot trial of its Impella CP heart pump that will clear the way for a pivotal that could nearly double the device’s total addressable market. The company announced on Sunday that a pilot study of its Impella CP, used to […]
Pilot trial of Abiomed’s Impella as heart attack treatment meets endpoints, pivotal to follow
A pilot trial exploring the use of Abiomed‘s (NSDQ:ABMD) Impella heart pump as a treatment for reducing the severity of heart attacks has met its primary safety and feasibility endpoints, clearing the way for a pivotal trial, according to primary investigator Dr. Navin Kapur. Results from the pivotal, if successful, could “change the paradigm of […]
Abiomed shreds fiscal Q2 forecasts
Abiomed (NSDQ:ABMD) today posted fiscal second-quarter numbers that shredded the consensus forecast and raised its outlook on the rest of the year, sending share prices up sharply today. The Danvers, Mass.-based cardiac assist device maker more than doubled its profits to $50.1 million, or $1.09 per share, on sales of $181.8 million, for a 104.6% […]
Abiomed joins Protembis $10m Series A
Protembis said today it closed a $10 million Series A round, joined by cardiovascular device-focused Abiomed (NSDQ:ABMD), to support its embolic cerebral protection device. The round was joined by Abiomed, Aachen and Mönchengladbach GmbH’s Seed Fonds III and a number of family offices and angel investors, the Aachen, Germany-based company said. “Patient safety should always be our […]
- 1
- 2
- 3
- …
- 23
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube